DE60131450T2 - Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle - Google Patents
Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle Download PDFInfo
- Publication number
- DE60131450T2 DE60131450T2 DE60131450T DE60131450T DE60131450T2 DE 60131450 T2 DE60131450 T2 DE 60131450T2 DE 60131450 T DE60131450 T DE 60131450T DE 60131450 T DE60131450 T DE 60131450T DE 60131450 T2 DE60131450 T2 DE 60131450T2
- Authority
- DE
- Germany
- Prior art keywords
- yeast
- plasminogen
- microplasminogen
- cell
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000013598 vector Substances 0.000 title abstract description 21
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract description 3
- 238000004519 manufacturing process Methods 0.000 title description 7
- 102000013566 Plasminogen Human genes 0.000 claims abstract description 38
- 108010051456 Plasminogen Proteins 0.000 claims abstract description 38
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 29
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 21
- 108010068982 microplasmin Proteins 0.000 claims description 35
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 210000005253 yeast cell Anatomy 0.000 claims description 17
- 150000001413 amino acids Chemical group 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 13
- 241000235648 Pichia Species 0.000 claims description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 11
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 11
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 11
- 230000003197 catalytic effect Effects 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 11
- 229940127126 plasminogen activator Drugs 0.000 claims description 11
- 239000004472 Lysine Substances 0.000 claims description 8
- 229960003646 lysine Drugs 0.000 claims description 8
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 7
- 229960000401 tranexamic acid Drugs 0.000 claims description 7
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 6
- 101710145796 Staphylokinase Proteins 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 230000000087 stabilizing effect Effects 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 3
- 229960002684 aminocaproic acid Drugs 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000003929 acidic solution Substances 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 abstract description 36
- 108010049112 miniplasminogen Proteins 0.000 abstract description 13
- 206010061216 Infarction Diseases 0.000 abstract description 12
- 230000002490 cerebral effect Effects 0.000 abstract description 12
- 230000007574 infarction Effects 0.000 abstract description 12
- 230000000302 ischemic effect Effects 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 10
- 230000004913 activation Effects 0.000 abstract description 8
- 230000006641 stabilisation Effects 0.000 abstract description 4
- 108010088842 Fibrinolysin Proteins 0.000 description 34
- 229940012957 plasmin Drugs 0.000 description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- 238000001802 infusion Methods 0.000 description 19
- 208000028867 ischemia Diseases 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 210000001367 artery Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 108010049003 Fibrinogen Proteins 0.000 description 14
- 102000008946 Fibrinogen Human genes 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 238000003776 cleavage reaction Methods 0.000 description 14
- 229940012952 fibrinogen Drugs 0.000 description 14
- 230000007017 scission Effects 0.000 description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 102000009123 Fibrin Human genes 0.000 description 11
- 108010073385 Fibrin Proteins 0.000 description 11
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 11
- 241000235058 Komagataella pastoris Species 0.000 description 11
- 229950003499 fibrin Drugs 0.000 description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 10
- 208000006011 Stroke Diseases 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229910052802 copper Inorganic materials 0.000 description 9
- 239000010949 copper Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 101710194180 Alcohol oxidase 1 Proteins 0.000 description 8
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 238000000137 annealing Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 108700006280 human microplasminogen Proteins 0.000 description 8
- 102000046729 human microplasminogen Human genes 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 108010084455 Zeocin Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000003527 fibrinolytic agent Substances 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000002085 persistent effect Effects 0.000 description 7
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 230000002537 thrombolytic effect Effects 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002583 angiography Methods 0.000 description 6
- 208000034158 bleeding Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000003480 fibrinolytic effect Effects 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 230000001732 thrombotic effect Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 208000032382 Ischaemic stroke Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000013011 mating Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000007974 sodium acetate buffer Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 201000008247 brain infarction Diseases 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000001259 mesencephalon Anatomy 0.000 description 4
- 108010015052 miniplasmin Proteins 0.000 description 4
- 229940105631 nembutal Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229960005356 urokinase Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical group OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 101150051118 PTM1 gene Proteins 0.000 description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 108010023197 Streptokinase Proteins 0.000 description 3
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 3
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 108010049041 glutamylalanine Proteins 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 108010087750 lysyl-plasminogen Proteins 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000003388 posterior cerebral artery Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 229960005202 streptokinase Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000000966 temporal muscle Anatomy 0.000 description 3
- 230000009424 thromboembolic effect Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- SJJHXJDSNQJMMW-SRVKXCTJSA-N Glu-Lys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SJJHXJDSNQJMMW-SRVKXCTJSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 206010051151 Hyperviscosity syndrome Diseases 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010038563 Reocclusion Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 206010058990 Venous occlusion Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 230000010455 autoregulation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 208000024980 claudication Diseases 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000009101 premedication Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011158 quantitative evaluation Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000013606 secretion vector Substances 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102220643871 39S ribosomal protein L9, mitochondrial_E99Q_mutation Human genes 0.000 description 1
- 102220643850 39S ribosomal protein L9, mitochondrial_K35A_mutation Human genes 0.000 description 1
- 101150061183 AOX1 gene Proteins 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000156948 Aphantopus hyperantus Species 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- 206010051093 Cardiopulmonary failure Diseases 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 206010049669 Dyscalculia Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019013 Haemorrhagic infarction Diseases 0.000 description 1
- 102220525300 Heat shock 70 kDa protein 6_K74R_mutation Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500025915 Homo sapiens Angiostatin Proteins 0.000 description 1
- 101001041673 Homo sapiens Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing] Proteins 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010083687 Ion Pumps Proteins 0.000 description 1
- 206010060840 Ischaemic cerebral infarction Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 101150045458 KEX2 gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 102100021404 Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing] Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229940122791 Plasmin inhibitor Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101150028158 STE13 gene Proteins 0.000 description 1
- 101100043665 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) STE13 gene Proteins 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 201000006559 Vertebrobasilar insufficiency Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000008822 capillary blood flow Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 229940105784 coagulation factor xiii Drugs 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229940068840 d-biotin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 230000001471 fibrinogenolytic effect Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000004343 lateral medullary syndrome Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000001636 ophthalmic artery Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002806 plasmin inhibitor Substances 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000037047 psychomotor activity Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- GLLPUTYLZIKEGF-HAVVHWLPSA-N ridogrel Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(=N/OCCCCC(=O)O)\C1=CC=CN=C1 GLLPUTYLZIKEGF-HAVVHWLPSA-N 0.000 description 1
- 229950006674 ridogrel Drugs 0.000 description 1
- 102200072128 rs104894671 Human genes 0.000 description 1
- 102220057396 rs150354152 Human genes 0.000 description 1
- 102220165777 rs534539796 Human genes 0.000 description 1
- 102220271808 rs767472238 Human genes 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0031196 | 2000-12-21 | ||
| GB0031196A GB0031196D0 (en) | 2000-12-21 | 2000-12-21 | Recombinant human plasminogen and plasmin: methods for high yield production stabilization and use for treatment |
| GB0116690 | 2001-07-09 | ||
| GB0116690A GB0116690D0 (en) | 2001-07-09 | 2001-07-09 | Human plasminogen and plasmin |
| GB0116702A GB0116702D0 (en) | 2001-07-09 | 2001-07-09 | Human plasminogen and plasmin |
| GB0116702 | 2001-07-09 | ||
| PCT/BE2001/000217 WO2002050290A1 (en) | 2000-12-21 | 2001-12-20 | A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60131450D1 DE60131450D1 (de) | 2007-12-27 |
| DE60131450T2 true DE60131450T2 (de) | 2008-10-16 |
Family
ID=27256020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60131450T Expired - Lifetime DE60131450T2 (de) | 2000-12-21 | 2001-12-20 | Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7445775B2 (https=) |
| EP (1) | EP1343903B1 (https=) |
| JP (2) | JP4047170B2 (https=) |
| AT (1) | ATE378413T1 (https=) |
| AU (1) | AU2002218890A1 (https=) |
| CY (1) | CY1107866T1 (https=) |
| DE (1) | DE60131450T2 (https=) |
| DK (1) | DK1343903T3 (https=) |
| ES (1) | ES2296705T3 (https=) |
| PT (1) | PT1343903E (https=) |
| WO (1) | WO2002050290A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6998121B2 (en) * | 2003-01-23 | 2006-02-14 | Milkhaus Laboratory, Inc. | Method of treatment of connective tissue disorders by administration of streptolysin O |
| DE10390418D2 (de) * | 2002-02-06 | 2005-01-13 | N Zyme Biotec Gmbh | Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen |
| AU2003210137A1 (en) * | 2002-02-06 | 2003-09-02 | N-Zyme Biotec Gmbh | Method for producing recombinant proteins in micro-organisms |
| GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
| KR100595864B1 (ko) * | 2004-01-27 | 2006-06-30 | 재단법인 목암생명공학연구소 | 형질전환 사카로마이세스 세레비지애 균주 및 이를 이용한ｌｋ8 단백질의 생산방법 |
| CN1938427A (zh) | 2004-02-11 | 2007-03-28 | 比奥莱克斯公司 | 纤溶酶原和微纤溶酶原在浮萍中的表达 |
| CN102660564B (zh) * | 2004-04-22 | 2013-05-08 | 泰勒克里斯生物治疗学公司 | 重组修饰的纤溶酶 |
| CN100368524C (zh) * | 2005-05-17 | 2008-02-13 | 上海大学 | 巴士德毕赤酵母gs115/pfk-k5的高密度发酵方法 |
| US20070134231A1 (en) * | 2005-12-13 | 2007-06-14 | Jani Dharmendra M | Method for prolonging activity of autodegradable enzymes and compositions thereof |
| US20070134230A1 (en) * | 2005-12-13 | 2007-06-14 | Jani Dharmendra M | Method for prolonging activity of autodegradable enzymes |
| US20070196350A1 (en) * | 2006-02-22 | 2007-08-23 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
| US20070212358A1 (en) * | 2006-03-10 | 2007-09-13 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
| PL2220221T3 (pl) * | 2007-11-29 | 2015-07-31 | Grifols Therapeutics Inc | Rekombinacyjnie zmodyfikowana plazmina |
| WO2009104199A1 (en) * | 2008-02-19 | 2009-08-27 | Biocon Limited | A method of obtaining purified heterologous insulins expressed in yeast |
| MX2010013282A (es) | 2008-06-04 | 2010-12-21 | Talecris Biotherapeutics Inc | Composicion, metodo y kit para la preparacion de plasmina. |
| HUE025670T2 (en) | 2009-03-03 | 2016-04-28 | Grifols Therapeutics Inc | A method for producing plasminogen |
| WO2011004011A1 (en) | 2009-07-10 | 2011-01-13 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| ES2534911T3 (es) | 2009-08-28 | 2015-04-30 | Thrombogenics N.V. | Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía |
| JP6085568B2 (ja) | 2011-01-05 | 2017-02-22 | スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ | プラスミノーゲンおよびプラスミンの変異体 |
| US9644196B2 (en) | 2011-08-12 | 2017-05-09 | Thrombogenics Nv | Plasminogen and plasmin variants |
| CN110066783B (zh) * | 2019-05-16 | 2021-07-13 | 重庆派金生物科技有限公司 | 一种无自切形式的微纤溶酶制备方法 |
| CN113355309B (zh) * | 2021-08-10 | 2021-11-05 | 迈威(上海)生物科技股份有限公司 | 重组截短型人纤维蛋白溶酶制备工艺 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4774087A (en) * | 1987-08-14 | 1988-09-27 | Northwestern University | Micro-size fibrinolytic plasmin |
| WO1990013640A1 (en) | 1989-05-01 | 1990-11-15 | The University Of Notre Dame Du Lac | Methods and materials for expression of human plasminogen in a eukaryotic cell system |
| GB9222758D0 (en) * | 1992-10-29 | 1992-12-09 | British Bio Technology | Proteins and nucleic acids |
| US5288489A (en) | 1991-08-28 | 1994-02-22 | Orion Therapeutic Systems, Inc. | Fibrinolysis and fibrinogenolysis treatment |
| ATE349226T1 (de) * | 1998-09-29 | 2007-01-15 | Leuven Res & Dev Vzw | Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle |
-
2001
- 2001-12-20 JP JP2002551170A patent/JP4047170B2/ja not_active Expired - Lifetime
- 2001-12-20 DK DK01271444T patent/DK1343903T3/da active
- 2001-12-20 ES ES01271444T patent/ES2296705T3/es not_active Expired - Lifetime
- 2001-12-20 US US10/450,976 patent/US7445775B2/en not_active Expired - Lifetime
- 2001-12-20 AU AU2002218890A patent/AU2002218890A1/en not_active Abandoned
- 2001-12-20 PT PT01271444T patent/PT1343903E/pt unknown
- 2001-12-20 AT AT01271444T patent/ATE378413T1/de active
- 2001-12-20 WO PCT/BE2001/000217 patent/WO2002050290A1/en not_active Ceased
- 2001-12-20 DE DE60131450T patent/DE60131450T2/de not_active Expired - Lifetime
- 2001-12-20 EP EP01271444A patent/EP1343903B1/en not_active Expired - Lifetime
-
2007
- 2007-03-15 JP JP2007067213A patent/JP4250660B2/ja not_active Expired - Lifetime
-
2008
- 2008-01-25 CY CY20081100089T patent/CY1107866T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002218890A1 (en) | 2002-07-01 |
| JP4047170B2 (ja) | 2008-02-13 |
| DE60131450D1 (de) | 2007-12-27 |
| ES2296705T3 (es) | 2008-05-01 |
| JP4250660B2 (ja) | 2009-04-08 |
| US7445775B2 (en) | 2008-11-04 |
| EP1343903A1 (en) | 2003-09-17 |
| EP1343903B1 (en) | 2007-11-14 |
| PT1343903E (pt) | 2008-02-18 |
| CY1107866T1 (el) | 2013-06-19 |
| JP2004526427A (ja) | 2004-09-02 |
| DK1343903T3 (da) | 2008-03-10 |
| US20040071676A1 (en) | 2004-04-15 |
| WO2002050290A1 (en) | 2002-06-27 |
| ATE378413T1 (de) | 2007-11-15 |
| JP2007195558A (ja) | 2007-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60131450T2 (de) | Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle | |
| JP2007195558A6 (ja) | 活性化されたミクロプラスミンの産生方法 | |
| DE3617753C2 (https=) | ||
| US5143836A (en) | Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda pl promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof | |
| DE3617752C2 (https=) | ||
| KR20120050442A (ko) | 플라스미노겐 및 플라스민의 변이체 | |
| US20090136557A1 (en) | Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots | |
| JPH0378375B2 (https=) | ||
| WO2003066842A2 (de) | Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen | |
| JP2010184930A (ja) | 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 | |
| DE69432608T2 (de) | Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp | |
| EP0669394B1 (de) | Bifunktionelle Urokinasevarianten mit verbesserten fibrinolytischen Eigenschaften und thrombinhemmender Wirkung | |
| JP2011178687A (ja) | 造血細胞移植に伴う疼痛の予防および／または治療剤 | |
| JP2009196927A (ja) | 血管障害に起因する網膜障害の進展阻害または治療剤 | |
| JP2003517020A (ja) | 線維素溶解プロテイナーゼを局所投与する方法 | |
| DE69003342T2 (de) | Pharmazeutische Zusammensetzungen. | |
| JPH0272124A (ja) | 組織プラスミノーゲン活性化因子製剤 | |
| JP3113787B2 (ja) | 脳梗塞予防治療剤 | |
| CN117100845A (zh) | 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途 | |
| KR20230009461A (ko) | 혈전성 또는 출혈성 질환의 치료에 사용하기 위한 서방성 플라스미노겐 활성제 제형 | |
| EA007654B1 (ru) | Способ лечения закупорки стационарного катетера с использованием фибринолитических металлопротеиназ | |
| HK1057328A1 (zh) | 治疗中风的无神经毒性血纤维蛋白溶酶原激活因子 | |
| WO1999009184A1 (de) | Plasminogenaktivator mit verbesserter zymogenität und verminderter fibrinbindung | |
| DE4443273A1 (de) | Verwendung der Proteasedomäne von humanem Plasminogenaktivator zur Behandlung von thromboembolischen Erkrankungen | |
| HK1057328B (en) | Non-neurotoxic plasminogen activating factors for treating stroke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: THROMBOGENICS N.V., LEUVEN, BE |
|
| 8364 | No opposition during term of opposition |